Free Trial

vTv Therapeutics (VTVT) Competitors

vTv Therapeutics logo
$16.01 +1.11 (+7.45%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$15.93 -0.08 (-0.50%)
As of 07/8/2025 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VTVT vs. CTMX, OGI, GNFT, FDMT, IPHA, VTYX, DERM, PBYI, DMAC, and SPRO

Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

vTv Therapeutics vs. Its Competitors

vTv Therapeutics (NASDAQ:VTVT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

vTv Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.

vTv Therapeutics currently has a consensus price target of $35.50, suggesting a potential upside of 121.74%. CytomX Therapeutics has a consensus price target of $5.33, suggesting a potential upside of 122.22%. Given CytomX Therapeutics' higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
CytomX Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

CytomX Therapeutics has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
vTv Therapeutics$1.02M50.07-$18.46M-$3.01-5.32
CytomX Therapeutics$138.10M1.40$31.87M$0.485.00

In the previous week, CytomX Therapeutics had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.00 equaled CytomX Therapeutics'average media sentiment score.

Company Overall Sentiment
vTv Therapeutics Neutral
CytomX Therapeutics Neutral

CytomX Therapeutics has a net margin of 28.22% compared to vTv Therapeutics' net margin of 0.00%. vTv Therapeutics' return on equity of -121.46% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
vTv TherapeuticsN/A -121.46% -46.75%
CytomX Therapeutics 28.22%-553.71%32.21%

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats vTv Therapeutics on 12 of the 14 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTVT vs. The Competition

MetricvTv TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$47.60M$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-5.3220.8026.9620.11
Price / Sales50.07286.27430.20119.79
Price / CashN/A41.1936.8257.86
Price / Book3.577.487.985.56
Net Income-$18.46M-$55.04M$3.16B$248.40M
7 Day Performance6.31%2.44%2.39%4.67%
1 Month Performance-0.56%1.90%2.18%6.64%
1 Year Performance-20.39%4.35%33.82%21.31%

vTv Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTVT
vTv Therapeutics
1.9833 of 5 stars
$16.01
+7.4%
$35.50
+121.7%
-11.5%$47.60M$1.02M-5.329
CTMX
CytomX Therapeutics
3.9205 of 5 stars
$2.27
+0.9%
$5.33
+134.9%
+84.6%$181.40M$138.10M4.73170
OGI
Organigram Global
0.9599 of 5 stars
$1.35
flat
N/A-8.9%$180.82M$117.47M13.50860News Coverage
Gap Down
GNFT
GENFIT
1.5111 of 5 stars
$3.73
+3.2%
$13.00
+249.0%
-15.4%$180.49M$67.00M0.00120News Coverage
Positive News
Gap Up
FDMT
4D Molecular Therapeutics
2.2677 of 5 stars
$3.71
-3.4%
$29.56
+696.6%
-80.4%$177.89M$40K-1.17120
IPHA
Innate Pharma
2.5261 of 5 stars
$1.82
-1.9%
$11.00
+506.1%
-18.6%$170.53M$21.77M0.00220
VTYX
Ventyx Biosciences
2.3679 of 5 stars
$2.14
-8.5%
$10.00
+367.3%
-9.2%$166.52MN/A-1.2230
DERM
Journey Medical
1.8438 of 5 stars
$7.18
+0.6%
$9.50
+32.3%
+21.6%$166.33M$56.13M-18.4190Analyst Downgrade
PBYI
Puma Biotechnology
3.9065 of 5 stars
$3.43
+3.0%
$7.00
+104.1%
+20.5%$165.27M$230.50M4.45200
DMAC
DiaMedica Therapeutics
0.8711 of 5 stars
$3.90
+1.6%
$8.00
+105.1%
+18.1%$164.67MN/A-6.0920
SPRO
Spero Therapeutics
3.8735 of 5 stars
$2.90
-1.4%
$5.00
+72.4%
+131.5%$164.38M$47.98M-2.27150

Related Companies and Tools


This page (NASDAQ:VTVT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners